ArticleBMC pulmonary medicine2017
Serum concentrations of Krebs von den Lungen-6, surfactant protein D, and matrix metalloproteinase-2 as diagnostic biomarkers in patients with asbestosis and silicosis: a case-control study.
Article in BMC pulmonary medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 36 citations in OpenAlex.
- Development and validation of a magnetic nanoparticle-based chemiluminescent immunoassay for serum surfactant protein D in pulmonary diseases.Mikrochimica acta · 2026Article
- Serum KL-6 combined with immune/inflammatory biomarkers identifies complicated silicosis.BMC pulmonary medicine · 2026Article
- The emerging roles of microRNAs in pneumoconiosis: pathogenic mechanisms and clinical implications.Frontiers in cell and developmental biology · 2026Review
- Review
- Cytokine Profiles as Predictive Biomarkers of Disease Severity and Progression in Engineered Stone Silicosis: A Machine Learning Approach.Diagnostics (Basel, Switzerland) · 2025Article
- Serum Krebs von den Lungen-6 as a potential biomarker for early diagnosis of silicosis: a case-control study.BMC pulmonary medicine · 2025Article
- Serum concentrations of Krebs von den Lungen-6 as prognostic biomarker in patients with silicosis.Frontiers in medicine · 2025Article
- Global, regional, and national trends in the incidence of pneumoconiosis among populations aged 20 and above from 1990 to 2021.Frontiers in public health · 2025Article
- Impact of Occupational Cement Dust Exposure on Hematological Health Parameters: A Cross-Sectional Study.Cureus · 2024Article
- Article
- A comprehensive retrospect on the current perspectives and future prospects of pneumoconiosis.Frontiers in public health · 2024Review
- Development of a multi-laboratory integrated predictive model for silicosis utilizing machine learning: a retrospective case-control study.Frontiers in public health · 2024Article
- Plasma Cytokine Profiling Reveals Differences between Silicotic Patients with Simple Silicosis and Those with Progressive Massive Fibrosis Caused by Engineered Stone.International journal of molecular sciences · 2023Article
- Serum Osteopontin, KL-6, and Syndecan-4 as Potential Biomarkers in the Diagnosis of Coal Workers' Pneumoconiosis: A Case-Control Study.Pharmacogenomics and personalized medicine · 2023Article
- Biomonitoring Exposure and Early Diagnosis in Silicosis: A Comprehensive Review of the Current Literature.Biomedicines · 2022Review
- Early Detection Methods for Silicosis in Australia and Internationally: A Review of the Literature.International journal of environmental research and public health · 2021Review
- Serum neuron-specific enolase: A promising biomarker of silicosis.World journal of clinical cases · 2021Article
- Decreased Soluble Receptor of Advanced Glycation End Product Levels Correlated with Inflammation in Silicosis.Mediators of inflammation · 2020Article
- Integrated Analysis of lncRNA and mRNA Transcriptomes Reveals New Regulators of Ubiquitination and the Immune Response in Silica-Induced Pulmonary Fibrosis.BioMed research international · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundAsbestosis and silicosis are progressive pneumoconioses characterized by interstitial fibrosis following exposure to asbestos or silica dust. We evaluated the potential diagnostic biomarkers for these diseases.
methodsThe serum concentrations of Krebs von den Lungen-6 (KL-6), surfactant protein D (SP-D), and matrix metalloproteinase-2 (MMP-2), MMP-7, and MMP-9 were measured in 43 patients with asbestosis, 45 patients with silicosis, 40 dust-exposed workers (DEWs) without pneumoconiosis, and 45 healthy controls (HCs). Chest high-resolution computed tomography (HRCT) images were reviewed by experts blinded to the clinical data. According to the receiver operating characteristic (ROC) curve, the ideal level of each biomarker and its diagnostic sensitivity were obtained.
resultsThe serum KL-6 and MMP-2 concentrations were highest in patients with asbestosis, particularly in comparison with those in DEWs and HCs (P<0.05). The serum SP-D concentration was significantly higher in patients with asbestosis than in patients with silicosis, DEWs, and HCs (P<0.01), whereas no significant difference was noted among patients with silicosis, DEWs, and HCs. No significant difference in the serum MMP-7 or -9 concentration was found among patients with asbestosis, patients with silicosis, DEWs, or HCs. Among patients with asbestosis, the serum KL-6 concentration was significantly correlated with the lung fibrosis scores on HRCT and negatively correlated with the forced vital capacity (FVC) % predicted and diffusing capacity of the lung for carbon monoxide (DL
conclusionsKL-6, SP-D, and MMP-2 are available biomarkers for the adjuvant diagnosis of asbestosis and silicosis. The combination of all three biomarkers may improve the diagnostic sensitivity for asbestosis and silicosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.